Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Mol Cancer Ther.
2021 Oct;20(10):2049-2060. doi: 10.1158/1535-7163.MCT-20-1126. Epub 2021 Aug 10. PubMed PMID:
34376578; PubMed Central PMCID:
PMC9768695.
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.
Mol Carcinog.
2021 Mar;60(3):201-212. doi: 10.1002/mc.23284. PubMed PMID:
33595872.
Molecular therapeutics for anaplastic thyroid cancer.
Semin Cancer Biol.
2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25. PubMed PMID:
31991166; PubMed Central PMCID:
PMC7117889.
Genetics of Human Thyroid Cancer Cell Lines-Response.
Clin Cancer Res.
2019 Nov 15;25(22):6883-6884. doi: 10.1158/1078-0432.CCR-19-2531. PubMed PMID:
31732665; PubMed Central PMCID:
PMC7396876.
Cell Lines as Biological Models: Practical Steps for More Reliable Research.
Chem Res Toxicol.
2019 Sep 16;32(9):1733-1736. doi: 10.1021/acs.chemrestox.9b00215. Epub 2019 Jun 15. PubMed PMID:
31203605; PubMed Central PMCID:
PMC6748863.
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.
Clin Cancer Res.
2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8. PubMed PMID:
30737244; PubMed Central PMCID:
PMC6522280.
Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.
Mol Cancer Res.
2019 May;17(5):1036-1048. doi: 10.1158/1541-7786.MCR-18-1026. Epub 2019 Feb 7. PubMed PMID:
30733375; PubMed Central PMCID:
PMC6711777.
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis.
Oncogene.
2019 Apr;38(14):2565-2579. doi: 10.1038/s41388-018-0617-1. Epub 2018 Dec 10. PubMed PMID:
30531837; PubMed Central PMCID:
PMC6450711.
Research ethics dilemmas in thyroid disease.
Curr Opin Endocrinol Diabetes Obes.
2018 Oct;25(5):335-340. doi: 10.1097/MED.0000000000000429. Review. PubMed PMID:
30095478.
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Clin Cancer Res.
2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3. PubMed PMID:
29615459; PubMed Central PMCID:
PMC6030480.
Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.
Thyroid.
2018 Jun;28(6):739-747. doi: 10.1089/thy.2017.0706. PubMed PMID:
29774792; PubMed Central PMCID:
PMC6040202.
Development of new preclinical models to advance adrenocortical carcinoma research.
Endocr Relat Cancer.
2018 Apr;25(4):437-451. doi: 10.1530/ERC-17-0447. Epub 2018 Jan 25. PubMed PMID:
29371329; PubMed Central PMCID:
PMC5831504.
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Oncogenesis.
2018 Feb 28;7(2):23. doi: 10.1038/s41389-017-0015-5. PubMed PMID:
29487290; PubMed Central PMCID:
PMC5833015.
Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.
Oncotarget.
2017 Nov 28;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28. PubMed PMID:
29262541; PubMed Central PMCID:
PMC5732707.
FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes.
Mol Cancer Res.
2016 Sep;14(9):869-82. doi: 10.1158/1541-7786.MCR-16-0007. Epub 2016 Jun 3. PubMed PMID:
27259715; PubMed Central PMCID:
PMC5025360.
Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
Oncotarget.
2016 Aug 9;7(32):51619-51625. doi: 10.18632/oncotarget.10010. PubMed PMID:
27322211; PubMed Central PMCID:
PMC5239501.
The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
Mol Cancer Ther.
2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24. PubMed PMID:
27222538; PubMed Central PMCID:
PMC4975658.
Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models.
Horm Cancer.
2015 Jun;6(2-3):87-99. doi: 10.1007/s12672-015-0219-0. Epub 2015 Mar 24. PubMed PMID:
25800363; PubMed Central PMCID:
PMC4414894.
Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.
Oncotarget.
2015 Apr 30;6(12):10175-94. doi: 10.18632/oncotarget.3391. PubMed PMID:
25868388; PubMed Central PMCID:
PMC4496348.
Development and characterization of six new human papillary thyroid carcinoma cell lines.
J Clin Endocrinol Metab.
2015 Feb;100(2):E243-52. doi: 10.1210/jc.2014-2624. Epub 2014 Nov 26. PubMed PMID:
25427145; PubMed Central PMCID:
PMC4318904.
Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8.
J Clin Endocrinol Metab.
2014 Aug;99(8):E1436-44. doi: 10.1210/jc.2013-3636. Epub 2014 Apr 23. PubMed PMID:
24758177; PubMed Central PMCID:
PMC4121024.
mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.
J Clin Endocrinol Metab.
2014 Jul;99(7):E1368-75. doi: 10.1210/jc.2014-1171. Epub 2014 Apr 8. PubMed PMID:
24712572; PubMed Central PMCID:
PMC5393487.
Thyroid cancer cell line misidentification: an update.
J Clin Endocrinol Metab.
2013 Mar;98(3):956-7. doi: 10.1210/jc.2012-4182. PubMed PMID:
23472230; PubMed Central PMCID:
PMC3590476.
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Clin Cancer Res.
2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14. PubMed PMID:
22586301; PubMed Central PMCID:
PMC3931551.
Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.
Front Endocrinol (Lausanne).
2012;3:81. doi: 10.3389/fendo.2012.00081. eCollection 2012. PubMed PMID:
22723793; PubMed Central PMCID:
PMC3378072.
PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells.
PPAR Res.
2011;2011:171765. doi: 10.1155/2011/171765. Epub 2011 Dec 12. PubMed PMID:
22194735; PubMed Central PMCID:
PMC3236353.
Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology.
Thyroid.
2011 Sep;21(9):941-4. doi: 10.1089/thy.2011.2109.ed. PubMed PMID:
21877921.
Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.
Mol Cancer.
2010 May 21;9:117. doi: 10.1186/1476-4598-9-117. PubMed PMID:
20492683; PubMed Central PMCID:
PMC2887796.
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
J Clin Endocrinol Metab.
2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30. PubMed PMID:
19880792.
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells.
Endocr Rev.
2009 Dec 1;30(7):932. doi: 10.1210/edrv.30.7.9986. PubMed PMID:
28199516.
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Thyroid.
2009 Aug;19(8):825-35. doi: 10.1089/thy.2008.0362. PubMed PMID:
19500021; PubMed Central PMCID:
PMC2857444.
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
J Clin Endocrinol Metab.
2009 Jun;94(6):2199-203. doi: 10.1210/jc.2008-2511. Epub 2009 Mar 17. PubMed PMID:
19293266; PubMed Central PMCID:
PMC2690419.
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
Mol Cell.
2009 Apr 10;34(1):115-31. doi: 10.1016/j.molcel.2009.03.007. PubMed PMID:
19362540; PubMed Central PMCID:
PMC2735263.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J Clin Endocrinol Metab.
2008 Nov;93(11):4331-41. doi: 10.1210/jc.2008-1102. Epub 2008 Aug 19. PubMed PMID:
18713817; PubMed Central PMCID:
PMC2582569.
Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses.
J Biol Chem.
2006 Jul 28;281(30):20993-21003. doi: 10.1074/jbc.M604208200. Epub 2006 May 30. PubMed PMID:
16735500.
The characterization of protein post-translational modifications by mass spectrometry.
Acc Chem Res.
2003 Jun;36(6):453-61. doi: 10.1021/ar020143l. Review. PubMed PMID:
12809532.
Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter.
J Biol Chem.
2003 May 9;278(19):16863-72. doi: 10.1074/jbc.M213063200. Epub 2003 Mar 4. PubMed PMID:
12618435.
Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells.
Endocrine.
2003 Feb-Mar;20(1-2):3-12. doi: 10.1385/ENDO:20:1-2:3. PubMed PMID:
12668863.
Monitoring post-translational modification of proteins with allosteric ribozymes.
Nat Biotechnol.
2002 Aug;20(8):810-5. doi: 10.1038/nbt719. Epub 2002 Jul 15. PubMed PMID:
12118241.
Fibroblast growth factor activation of the rat PRL promoter is mediated by PKCdelta.
Mol Endocrinol.
2001 Sep;15(9):1517-28. doi: 10.1210/mend.15.9.0683. PubMed PMID:
11518800.
Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter.
Nucleic Acids Res.
2001 Mar 1;29(5):1251-60. doi: 10.1093/nar/29.5.1251. PubMed PMID:
11222776; PubMed Central PMCID:
PMC29733.
Phosphorylation of B-Myb regulates its transactivation potential and DNA binding.
J Biol Chem.
1999 Dec 17;274(51):36741-9. doi: 10.1074/jbc.274.51.36741. PubMed PMID:
10593981.
Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells. Identification of FGF response elements in the prolactin gene.
J Biol Chem.
1997 Dec 5;272(49):30852-9. doi: 10.1074/jbc.272.49.30852. PubMed PMID:
9388230.
What would you like to do?